IN2015DN03219A - - Google Patents

Info

Publication number
IN2015DN03219A
IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
Authority
IN
India
Prior art keywords
pridopidine
laquinimod
treating
neurodegenerative disorder
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Hayden
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2015DN03219A publication Critical patent/IN2015DN03219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3219DEN2015 2012-09-27 2013-09-27 IN2015DN03219A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IN2015DN03219A true IN2015DN03219A (ja) 2015-10-02

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3219DEN2015 IN2015DN03219A (ja) 2012-09-27 2013-09-27

Country Status (13)

Country Link
US (7) US20150209346A1 (ja)
EP (1) EP2900330A4 (ja)
CN (1) CN104902958A (ja)
AU (1) AU2013323131A1 (ja)
BR (1) BR112015006623A2 (ja)
CA (1) CA2884781A1 (ja)
EA (1) EA201590655A8 (ja)
HK (2) HK1211525A1 (ja)
IL (1) IL237742A0 (ja)
IN (1) IN2015DN03219A (ja)
MX (1) MX2015003608A (ja)
WO (1) WO2014052933A1 (ja)
ZA (1) ZA201502600B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PT2146961E (pt) * 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3590512A1 (en) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3151507C (en) 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
WO2020250234A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
JP5859438B2 (ja) * 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
MX2015003608A (es) 2015-06-05
EA201590655A1 (ru) 2015-12-30
US20180250285A1 (en) 2018-09-06
EP2900330A4 (en) 2016-05-25
HK1211525A1 (en) 2016-05-27
BR112015006623A2 (pt) 2017-07-04
US20180369228A1 (en) 2018-12-27
US20170319569A1 (en) 2017-11-09
AU2013323131A1 (en) 2015-05-07
EA201590655A8 (ru) 2016-07-29
ZA201502600B (en) 2016-06-29
US20140088140A1 (en) 2014-03-27
CN104902958A (zh) 2015-09-09
CA2884781A1 (en) 2014-04-03
IL237742A0 (en) 2015-05-31
EP2900330A1 (en) 2015-08-05
WO2014052933A1 (en) 2014-04-03
HK1214553A1 (zh) 2016-07-29
US20150209346A1 (en) 2015-07-30
US20190117639A1 (en) 2019-04-25
US20180133209A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
IN2015DN03219A (ja)
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
IN2013MU01155A (ja)
IN2013MU01252A (ja)
IN2013MU01154A (ja)
IN2013MU01249A (ja)
IN2013MU01247A (ja)